CalciMedica, Inc. (CALC)

NASDAQ: CALC · IEX Real-Time Price · USD
5.00
-0.48 (-8.76%)
Mar 29, 2023, 4:00 PM EDT - Market open
-8.76%
Market Cap 120.98M
Revenue (ttm) n/a
Net Income (ttm) -35.61M
Shares Out 1.53M
EPS (ttm) -23.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close 5.48
Day's Range 5.00 - 5.69
52-Week Range 4.88 - 284.20
Beta 1.20
Analysts n/a
Price Target n/a
Earnings Date May 8, 2023

About CALC

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 8
Stock Exchange NASDAQ
Ticker Symbol CALC
Full Company Profile

Financial Performance

Financial Statements

News

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected...

1 week ago - GlobeNewsWire

Graybug Announces Name and Trading Symbol Change

REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will becom...

1 week ago - GlobeNewsWire

GRAYBUG VISION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graybug Vision, Inc. - GRAY

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Graybug Vision...

1 month ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, GRAY, APEN, SAL

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols: APENSAL
4 months ago - PRNewsWire

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Graybug Vision, Inc. - GRAY

New York, New York--(Newsfile Corp. - December 5, 2022) -  Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national s...

4 months ago - Newsfile Corp

Shareholder Alert: Ademi LLP investigates whether Graybug Vision, Inc. has entered into a Fair Transaction with CalciMedica

MILWAUKEE , Nov. 22, 2022 /PRNewswire/ -- Ademi LLP is investigating Graybug (Nasdaq: GRAY) for possible breaches of fiduciary duty and other violations of law in its transaction with CalciMedica.  Cl...

4 months ago - PRNewsWire

GRAY STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Graybug Vision, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Graybug Vision, Inc. (NASDAQ: GRAY) and CalciMedica Inc. is fair to Graybug sharehold...

4 months ago - Business Wire

Graybug and CalciMedica Enter into Definitive Merger Agreement

– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases

4 months ago - GlobeNewsWire

Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing ...

4 months ago - GlobeNewsWire

Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments

BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today p...

8 months ago - GlobeNewsWire

Graybug to Present at the 2022 OIS Retina Innovation Summit

BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular ...

9 months ago - GlobeNewsWire

Graybug (GRAY) to Review Strategic Alternatives, Stock Up

Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.

9 months ago - Zacks Investment Research

Graybug Vision (GRAY) Stock Soars 35% on Strategic Review News

Today, investors in Graybug Vision and GRAY stock are cheering an announced strategic review, which could see a sale of the company. The post Graybug Vision (GRAY) Stock Soars 35% on Strategic Review ...

9 months ago - InvestorPlace

Graybug Announces Review of Strategic Alternatives

BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular ...

9 months ago - GlobeNewsWire

Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting

BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...

11 months ago - GlobeNewsWire

Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...

1 year ago - GlobeNewsWire

Graybug to Present at the 2022 ASCRS Annual Meeting

BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...

1 year ago - GlobeNewsWire

Graybug Vision Appoints Dirk Sauer to Board of Directors

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...

1 year ago - GlobeNewsWire

Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023

BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...

1 year ago - GlobeNewsWire

Graybug Vision to Host Virtual R&D Day on March 30, 2022

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...

1 year ago - GlobeNewsWire

Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments

Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET

1 year ago - GlobeNewsWire

Graybug to Participate in Three Upcoming Medical and Investor Conferences

BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...

1 year ago - GlobeNewsWire

Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline

BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...

1 year ago - GlobeNewsWire

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments

BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...

1 year ago - GlobeNewsWire

Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting

BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...

1 year ago - GlobeNewsWire